LIFE SCIENCES COMPANY
Sanophi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanophi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanophi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Medicine has made great progress in the last century. The average life expectancy of people worldwide has doubled in that time, thanks in large measure to the development of innovative treatments for serious diseases.
At Sanophi, we have a clear and resolute line for action: to contribute to the continuous advancement of health. As a company, and as individuals, Sanophi and its talented employees have always striven to advance the cause of health by developing treatments that prevent and treat diseases, while enhancing access to healthcare for the people around the world.
The expertise we have developed along the way has had a profound effect, particularly in the developing world. We have developed the first vaccine for the dengue virus, which infects 390 million people each year, and whose range is expanding due to climate change. Since the beginning of the year, first vaccinations campaigns have started in the Philippines. Thanks to systematic vaccination campaigns, we are close to eradicating polio; while over the last decade, sleeping sickness treatments have saved more than 180,000 lives.
Yet, there is much to be accomplished. A third of the world’s population still has no access to healthcare. And providing health products and services is just one part of the solution to tackle health inequalities that threat human development. As a leader, we must adapt the way we operate to meet our commitment to health.
We also must continue to uncover innovations to be shared widely among those in need. To do so, we know that the solution will emerge by listening to our stakeholders, and with a collaborative approach. For that, we partner with the Bill & Melinda Gates Foundation, the GAVI Alliance and the World Health Organization, amongst others.
Finally, our commitment to health goes beyond medicine, in part through our corporate responsibility approach and our dedication to make a real difference in the lives of people every day.
At Sanophi, we have strengthened the efficiency of our industrial resources and increased our presence in emerging countries, with a unique position with close to 40 sites that enables an offer adapted to region-specific characteristics and responsiveness to tenders.
Regardless of where our treatments are manufactured, our industrial network provides both healthcare professionals and patients with high quality and maximum safety.
We are experts at producing and distributing our healthcare solutions, whether a cold chain is required or not. Our flexible industrial network enables us to fully master medicine and vaccine lifecycle and control their quality.
From the plant to the patient: a medicine’s journey:
To protect patient, ensure product quality and preserve trust in the supply chain we also have a dedicated team that works day in day out coordinating company-wide efforts to fight attempts to counterfeit Sanophi’s products. Fighting counterfeit drugs represents a substantial public health challenge as international organizations consider that counterfeiting involves, on average, 10% of the global pharmaceutical market and counterfeiters increasingly use sophisticated means to produce fake medicines. At Sanophi, we address counterfeiting from the outset when defining packaging for products, incorporating anti-counterfeiting techniques into new product launches. We have developed labels, packaging with tamper-evident technology and data matrix codes to identify the contents.
From drug production to fight against counterfeit medicines:
Our industrial network, know-how and teams, thanks to a high quality and safety approach, deliver health solutions to millions of individuals across the globe.
ACCESS TO HEALTHCARE
Our Access to Medicines approach is on the ground, with long-lasting partners in disease areas where we have a recognized expertise: malaria, tuberculosis, neglected tropical diseases, epilepsy and mental illness. To promote access to healthcare to the greatest number, we developed a holistic approach that includes research on adapted drugs, development of preferential pricing policies in low-developed countries to make our solutions affordable, while developing information, education and communication programs to train healthcare professionals. In 2015, 280 programs have been implemented within the communities the most in need. 55 million patients received diagnosis, vaccination, treatment and targeted more than 260 million people through awareness campaigns.
WHERE WE ARE
With a presence in more than 100 countries and industrial sites in more than 40 countries, our industrial network, know-how and teams deliver health solutions to millions of individuals with high quality and maximum safety, regardless wherever they are manufactured.
In January 2012, Sanophi moved its head office location to 54, Rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent.
Sanophi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominant style of the area surrounding the François Mitterrand Library. After Sanophi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris. In June 2015, the seat was moved to Gentilly, just south of Paris.
The company is administered by a Board of Directors, represented by the Chairman. Our CEO directs and acts on behalf of the company. He chairs the Executive Committee, which is composed of permanent members.
The appointment of Diane Souza and Thomas Südhof as members of the Board was submitted to the 2016 Annual General Meeting. Diane Souza is the former CEO of UnitedHealthcare Specialty Benefits, with over 25 years of managed care and health benefits experience. Thomas Südhof, MD, is the Avram Goldstein Professor in the School of Medicine of Stanford University, as well as a Professor of Molecular & Cellular Physiology, Psychiatry, and Neurology. He won the Nobel Prize in Physiology or Medicine in 2013.
Serge Weinberg has been Chairman of the Board of Directors since May 17, 2010.
Preventing and Treating
January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.
January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes